They are relatively inexpensive to manufacture, and sufficiently robust to retain activity after centrifugation or filtration for recycling, and active in both in aqueous and organic media.
These compounds are active against wild type reverse transcriptase (RT) and retain activity against clinically important mutants.
Clearly, because a protein is active in a cultured cell assay, it cannot be assumed to retain activity in vivo.
These results were surprising, because the presence of an m-trifluoromethyl group was previously shown to be important to retain activity of related kinase inhibitors but, as shown here, is not essential for activation of IRE1α-KR43.
Most noticeably, they retain activity against the multidrug resistant MES-SA/Dx5 subline, showing resistant factors close to 1.
We also show that these dual-acting agents retain activity against HDAC and Topo I, and potently arrest cancer proliferation.
Here, we reveal the structural basis for how these inhibitors retain activity against a disease-relevant, drug-resistant kinase mutant, while maintaining Src specificity.
Taken together, our results offer a route for production and solution-state characterization that supports renewed effort in CPG2 structural biology as well as design of significantly truncated CPG2 proteins, which retain activity while yielding (potentially) improved immunogenicity.
Moreover, because CFP and YFP fusions generally retain activity and maintain their normal subcellular localizations, the detection of CFP YFP FRET in live cells typically reflects the steady-state association of functional proteins in their native states.
The compounds exhibited significant cytotoxic activity against the tested cell lines and in addition they retain activity against the multidrug resistant MES-SA/D × 5 subline, showing resistant factors close to 1.
The ability to develop aptamers that retain activity in multiple organisms facilitates preclinical development.
